Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

538
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
538
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

933
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
933
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

764
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
764

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Angiogenic Gene Therapy for Lower Extremity Ischemia: Experimental Advances and Clinical Experience.

Cells·2026
Same author

Safety of Adeno-Associated Viral Vectors in Gene Therapy: Mechanisms of Toxicity, Clinical Risks, and Strategies for Their Minimization.

International journal of molecular sciences·2026
Same author

Molecular and Genetic Aspects of Lipid Metabolism Disorders and Potential Targets for Gene Therapy.

Journal of lipid and atherosclerosis·2026
Same author

Influence of Eating Behavior and Dietary Patterns on Gut Microbiota Formation in Children with Autism Spectrum Disorder.

Nutrients·2026
Same author

Pompe Disease: Pathogenesis, Molecular Mechanisms, Neurological Aspects, Diagnostics and Modern Therapeutic Approaches.

International journal of molecular sciences·2026
Same author

The Simultaneous Prevention of Multiple Diseases: A "One Ring to Rule Them All" Framework for Redox-Driven Health and Longevity.

Nutrients·2026

Related Experiment Video

Updated: Jul 12, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.4K

T-Lymphocytes Activated by Dendritic Cells Loaded by Tumor-Derived Vesicles Decrease Viability of Melanoma Cells In

Ivan Yurevich Filin1, Yuriy Pavlovich Mayasin1, Chulpan Bulatovna Kharisova1

  • 1Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.

Current Issues in Molecular Biology
|October 27, 2023
PubMed
Summary

This study shows that modified T-cells, activated by dendritic cells loaded with tumor vesicles, effectively target and reduce melanoma cell viability, offering a promising new avenue for cancer immunotherapy.

Keywords:
GM-CSFantigen presentationantitumor vaccinecytochalasin Bcytotoxic effectdendritic cellsimmunotherapyinduced vesicles

More Related Videos

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.3K
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

11.9K

Related Experiment Videos

Last Updated: Jul 12, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.4K
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.3K
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

11.9K

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Immunotherapy harnesses the immune system to fight cancer.
  • Dendritic cell vaccines are a key immunotherapy strategy.
  • They activate T-lymphocytes to target tumor cells.

Purpose of the Study:

  • To investigate the effect of dendritic cells loaded with tumor-derived vesicles on melanoma cell viability.
  • To assess the anti-melanoma activity of T-cells activated by these modified dendritic cells.

Main Methods:

  • Dendritic cells were loaded with tumor-derived vesicles.
  • These modified dendritic cells were used to activate T-cells.
  • The cytotoxic activity of activated T-cells against melanoma cells was evaluated in vitro.

Main Results:

  • Modified T-cells demonstrated significant anti-melanoma activity.
  • A notable decrease in melanoma cell viability was observed.
  • This indicates potent T-lymphocyte activation against tumor cells.

Conclusions:

  • Dendritic cells processed with tumor-derived vesicles can enhance T-cell anti-melanoma activity.
  • This approach shows potential for developing novel melanoma immunotherapies.
  • Further research into T-lymphocyte activation mechanisms is warranted.